CARDAMYST (etripamil) is a prescription nasal spray indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) in adults.
CARDAMYST (etripamil) nasal spray is a pharmaceutical product developed by Milestone Pharmaceuticals USA, INC. It functions as a rapid-onset calcium channel blocker designed for self-administration by patients. The product is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adult patients.
The nasal spray device delivers a specific dosage of etripamil to the nasal mucosa, offering a portable and non-invasive treatment option for sudden rapid heart rate episodes outside of a hospital setting. Usage involves administering the spray into the nostrils upon the onset of symptoms, subject to specific dosage guidelines and safety precautions outlined in the prescribing information.
Latest manuals from manuals+ curated for this brand.
Common questions about manuals, registration, and support for this brand.
CARDAMYST is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
It is for intranasal use only. The initial dosage is 70 mg administered as two nasal sprays (one spray into each nostril). If symptoms persist after 10 minutes, a second dose may be administered.
The most frequent adverse reactions observed include nasal discomfort, nasal congestion, rhinorrhea, throat irritation, and epistaxis.
It is contraindicated in patients with hypersensitivity to etripamil, severe heart failure (NYHA Class II-IV), certain types of AV block without a pacemaker, sick sinus syndrome, or Wolff-Parkinson-White (WPW) syndrome.
The background risk of major birth defects and miscarriage is unknown. Consult a healthcare provider before using this medication during pregnancy.